CA2627351C - Lipophilic vehicle-based dual controlled release matrix system - Google Patents

Lipophilic vehicle-based dual controlled release matrix system Download PDF

Info

Publication number
CA2627351C
CA2627351C CA2627351A CA2627351A CA2627351C CA 2627351 C CA2627351 C CA 2627351C CA 2627351 A CA2627351 A CA 2627351A CA 2627351 A CA2627351 A CA 2627351A CA 2627351 C CA2627351 C CA 2627351C
Authority
CA
Canada
Prior art keywords
agents
rate controlling
soft capsule
matrix
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2627351A
Other languages
English (en)
French (fr)
Other versions
CA2627351A1 (en
Inventor
Karunakar Sukuru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Patheon Softgels Inc
Original Assignee
Banner Pharmacaps Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banner Pharmacaps Inc filed Critical Banner Pharmacaps Inc
Publication of CA2627351A1 publication Critical patent/CA2627351A1/en
Application granted granted Critical
Publication of CA2627351C publication Critical patent/CA2627351C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2627351A 2005-10-26 2006-10-26 Lipophilic vehicle-based dual controlled release matrix system Expired - Fee Related CA2627351C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73051405P 2005-10-26 2005-10-26
US60/730,514 2005-10-26
PCT/US2006/041722 WO2007050724A2 (en) 2005-10-26 2006-10-26 Lipophilic vehicle-based dual controlled release matrix system as capsule fill

Publications (2)

Publication Number Publication Date
CA2627351A1 CA2627351A1 (en) 2007-05-03
CA2627351C true CA2627351C (en) 2012-05-01

Family

ID=37968540

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2627351A Expired - Fee Related CA2627351C (en) 2005-10-26 2006-10-26 Lipophilic vehicle-based dual controlled release matrix system

Country Status (6)

Country Link
US (1) US8293270B2 (https=)
EP (1) EP1951208A2 (https=)
JP (2) JP5406529B2 (https=)
CN (1) CN101351196B (https=)
CA (1) CA2627351C (https=)
WO (1) WO2007050724A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2593047T3 (es) 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
HUE073014T2 (hu) 2007-04-25 2025-12-28 Opko Renal Llc Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén
CA2689434C (en) * 2007-06-04 2017-09-26 Shear/Kershman Laboratories, Inc. Tamper resistant lipid-based oral dosage form for opioid agonists
US8177950B2 (en) * 2007-11-21 2012-05-15 Tennessee Technological University Thermoresponsive microparticle composite hydrogels for electrophoresis
EP2281058B1 (en) 2008-04-02 2016-06-29 Opko Ireland Global Holdings, Ltd. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
CA2739882A1 (en) * 2008-10-22 2010-04-29 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition improving intestinal absorption
WO2011123476A1 (en) 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
EP2782603A1 (en) 2011-11-25 2014-10-01 Danmarks Tekniske Universitet Formulation of solid nano-sized particles in a gel-forming system
US20150250751A1 (en) * 2012-10-16 2015-09-10 Wockhardt Limited Pharmaceutical compositions of diclofenac or salts thereof
WO2014060857A1 (en) * 2012-10-19 2014-04-24 Wockhardt Limited Pharmaceutical compositions of diclofenac or salts thereof
US10420729B2 (en) 2013-03-15 2019-09-24 R.P. Scherer Technologies, Llc Abuse resistant capsule
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
ES2713157T3 (es) 2014-02-28 2019-05-20 Banner Life Sciences Llc Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US10182992B2 (en) 2014-04-07 2019-01-22 Patheon Softgels Inc. Abuse-deterrent controlled release formulations
US10772842B2 (en) 2015-01-09 2020-09-15 Patheon Softgels Inc. Abuse-deterrent opioids
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
WO2017189621A1 (en) * 2016-04-26 2017-11-02 Symbiotic Health Inc. Stable macroemulsion for oral delivery of solubilized peptides, protein, and cellular therapeutics
EA202092092A1 (ru) * 2018-03-15 2021-02-15 Сересин Инк. Фармацевтические композиции с высокими лекарственными нагрузками среднецепочечных триглицеридов и связанные с ними способы
WO2020053665A2 (en) * 2018-09-13 2020-03-19 Ftf Pharma Private Limited Non-aqueous chemotherapeutic suspensions for oral dosage
EP3863603A1 (en) * 2018-10-08 2021-08-18 Chanelle Pharmaceuticals Manufacturing Ltd. A soft-gel capsule formulation, method of manufacture and use thereof
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2016A (en) * 1841-03-26 Mode of constructing fireplaces and chimney-staoks ii
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
CA2017916C (en) * 1989-06-07 1999-02-02 Minoru Aoki Etoposide preparations
US5498422A (en) * 1991-04-08 1996-03-12 Nippon Shinyaku Company Limited Sustained release capsule
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
WO1995011668A1 (en) * 1993-10-29 1995-05-04 Reckitt & Colman Products Limited Gelatin capsule fill able to foam
GB9322314D0 (en) * 1993-10-29 1993-12-15 Scherer Ltd R P Foam generating capsules
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
FR2739558B1 (fr) * 1995-10-05 1997-11-28 Innothera Lab Sa Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale
FR2748209B1 (fr) 1996-05-06 1998-06-05 Adir Composition pharmaceutique a base de matrices lipophiles stabilisees pour la liberation controlee de principes actifs
US6027746A (en) * 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
IT1291362B1 (it) * 1997-05-13 1999-01-07 Vectorpharma Int Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi
JP4139909B2 (ja) * 1997-06-12 2008-08-27 キャタレント・ジャパン株式会社 ソフトカプセル用基剤
GB2328443B (en) * 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
BE1011363A3 (fr) * 1997-09-11 1999-08-03 Smb Technology Capsules semi-solides autoemulsionnables matricielles a action prolongee.
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
GB2331458B (en) 1997-11-21 2002-07-31 Gursharan Singh Moonga Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine
ATE429210T1 (de) 1998-01-20 2009-05-15 Applied Analytical Ind Inc Orale flüssige zusammensetzungen
FR2782006B1 (fr) * 1998-08-07 2002-04-19 Gattefosse Ets Sa Composition a liberation prolongee apte a former une micro-emulsion
US6251426B1 (en) * 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
EA200200415A1 (ru) 1999-09-27 2002-10-31 Американ Цианамид Компани Композиция фармацевтического носителя
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
DE60040729D1 (de) * 1999-12-20 2008-12-18 Shiseido Co Ltd Zubereitungen zur äusseren anwendung auf der haut enthaltend diethoxyethylsuccinat
US6491950B1 (en) * 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
US20030105141A1 (en) 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
WO2003061626A1 (en) * 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
IL164163A0 (en) 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
FR2838349B1 (fr) * 2002-04-15 2004-06-25 Laurence Paris Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication
US20050255152A1 (en) * 2002-04-18 2005-11-17 President And Fellows Of Harvard College System for enhanced targeted delivery
US20040033257A1 (en) * 2002-05-30 2004-02-19 Strides Inc. Pharmaceutical formulation in a drug delivery system and process for preparing the same
US7399488B2 (en) * 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
DK1545475T3 (da) 2002-10-01 2014-07-28 Banner Pharmacaps Inc Enterisk sammensætning til fremstillingen af blød kapselvæg
SI2279729T1 (sl) * 2003-07-17 2016-10-28 Banner Life Sciences, LLC Pripravki z nadziranim sproščanjem
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
AU2005206084A1 (en) * 2004-01-09 2005-08-04 Wyeth Microemulsions for pharmaceutical compositions
US20060286172A1 (en) * 2005-06-03 2006-12-21 Anu Mahashabde Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same

Also Published As

Publication number Publication date
CA2627351A1 (en) 2007-05-03
WO2007050724A2 (en) 2007-05-03
JP5406529B2 (ja) 2014-02-05
CN101351196A (zh) 2009-01-21
CN101351196B (zh) 2013-07-03
WO2007050724A3 (en) 2007-09-20
US8293270B2 (en) 2012-10-23
EP1951208A2 (en) 2008-08-06
JP2013216681A (ja) 2013-10-24
US20070092560A1 (en) 2007-04-26
JP2009513657A (ja) 2009-04-02

Similar Documents

Publication Publication Date Title
CA2627351C (en) Lipophilic vehicle-based dual controlled release matrix system
CA2627292C (en) Hydrophilic vehicle-based dual controlled release matrix system
US10632205B2 (en) Pharmaceutical composition having reduced abuse potential
US5433951A (en) Sustained release formulation containing captopril and method
EP1605916A1 (en) Solvent system of hardly soluble drug with improved elution rate
US20030165562A1 (en) Controlled release pharmaceutical composition
JP2007509155A (ja) クエチアピンを含有する薬剤
WO2009066146A2 (en) Stable solutions of sparingly soluble actives
CN102307576A (zh) 用于增强水不溶性活性剂的释放和吸收的方法
EA035515B1 (ru) Композиции на основе дейтерированного домперидона и способы терапии расстройств
CN1642537A (zh) 用于硬壳胶囊的布洛芬溶液
SK7342000A3 (en) Formulations comprising dissolved paroxetine
AU2005330320A1 (en) Improved formulations of fenofibrate containing menthol or a PEG/poloxamer mixture
US20020032220A1 (en) Formulations comprising dissolved paroxetine
CN106572980A (zh) 包含他喷他多的防篡改即释胶囊制剂
MX2008005470A (en) Lipophilic vehicle-based dual controlled release matrix system as capsule fill
MX2008005474A (en) Hydrophilic vehicle-based dual controlled release matrix system as capsule fill
CA2310407A1 (en) Formulations comprising dissolved paroxetine

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20201026